In conclusion, advances in understanding PCSK9 pitfalls in AD neurodegeneration, integrated with an in-depth characterization of pharmacological tools suitable for the management of this protein, are needed to fight this disabling disorder. This evidence concerns the gene PCSK9 and Alzheimer disease.